Search Results - "Baker, Brenda F"

Pharmacology of Antisense Drugs by Bennett, C. Frank, Baker, Brenda F, Pham, Nguyen, Swayze, Eric, Geary, Richard S

“…Recent studies have led to a greater appreciation of the diverse roles RNAs play in maintaining normal cellular function and how they contribute to disease…”
Get full text

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B by Geary, Richard S., Baker, Brenda F., Crooke, Stanley T.

“…Mipomersen (Kynamro ® ), a second-generation 2′- O -methoxyethyl chimeric antisense oligonucleotide (ASO), inhibits the synthesis of apolipoprotein B (apoB)…”
Get full text

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides by Graham, Mark J, Lee, Richard G, Brandt, Teresa A, Tai, Li-Jung, Fu, Wuxia, Peralta, Raechel, Yu, Rosie, Hurh, Eunju, Paz, Erika, McEvoy, Bradley W, Baker, Brenda F, Pham, Nguyen C, Digenio, Andres, Hughes, Steven G, Geary, Richard S, Witztum, Joseph L, Crooke, Rosanne M, Tsimikas, Sotirios

“…Angiopoietin-like 3 (ANGPTL3) inhibits endothelial lipase and lipoprotein lipase. Injection of antisense oligonucleotides targeting ANGPTL3 messenger RNA…”
Get full text

Targeting APOC3 in the Familial Chylomicronemia Syndrome by Gaudet, Daniel, Brisson, Diane, Tremblay, Karine, Alexander, Veronica J, Singleton, Walter, Hughes, Steven G, Geary, Richard S, Baker, Brenda F, Graham, Mark J, Crooke, Rosanne M, Witztum, Joseph L

“…In this study, investigators found that APOC3, a key regulator of triglyceride metabolism, had a profound and clinically relevant effect on triglyceride levels…”
Get full text

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study by Tsimikas, Sotirios, Prof, Viney, Nicholas J, BSc, Hughes, Steven G, MBBS, Singleton, Walter, MD, Graham, Mark J, MS, Baker, Brenda F, PhD, Burkey, Jennifer L, PhD, Yang, Qingqing, MS, Marcovina, Santica M, Prof, Geary, Richard S, PhD, Crooke, Rosanne M, PhD, Witztum, Joseph L, Prof

“…Summary Background Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic valve stenosis. No effective therapies to lower…”
Get full text

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans by Graham, Mark J, Lee, Richard G, Bell, Thomas A, Fu, Wuxia, Mullick, Adam E, Alexander, Veronica J, Singleton, Walter, Viney, Nick, Geary, Richard, Su, John, Baker, Brenda F, Burkey, Jennifer, Crooke, Stanley T, Crooke, Rosanne M

“…RATIONALE:Elevated plasma triglyceride levels have been recognized as a risk factor for the development of coronary heart disease. Apolipoprotein C-III…”
Get full text

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes by Digenio, Andres, Dunbar, Richard L, Alexander, Veronica J, Hompesch, Marcus, Morrow, Linda, Lee, Richard G, Graham, Mark J, Hughes, Steven G, Yu, Rosie, Singleton, Walter, Baker, Brenda F, Bhanot, Sanjay, Crooke, Rosanne M

“…To determine the effects of volanesorsen (ISIS 304801), a second-generation 2'-O-methoxyethyl chimeric antisense inhibitor of apolipoprotein (apo)C-III, on…”
Get full text

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers by Crooke, Stanley T, Baker, Brenda F, Kwoh, T Jesse, Cheng, Wei, Schulz, Dan J, Xia, Shuting, Salgado, Nelson, Bui, Huynh-Hoa, Hart, Christopher E, Burel, Sebastien A, Younis, Husam S, Geary, Richard S, Henry, Scott P, Bhanot, Sanjay

“…The common chemical and biological properties of antisense oligonucleotides provide the opportunity to identify and characterize chemical class effects across…”
Get full text

Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon by Hua, Yimin, Vickers, Timothy A, Baker, Brenda F, Bennett, C Frank, Krainer, Adrian R

“…Several strategies have been pursued to increase the extent of exon 7 inclusion during splicing of SMN2 (survival of motor neuron 2) transcripts, for eventual…”
Get full text

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy by Akdim, Fatima, MD, Stroes, Erik S.G., MD, PhD, Sijbrands, Eric J.G., MD, PhD, Tribble, Diane L., PhD, Trip, Mieke D., MD, PhD, Jukema, J. Wouter, MD, PhD, Flaim, JoAnn D., PhD, Su, John, PhD, Yu, Rosie, PhD, Baker, Brenda F., PhD, Wedel, Mark K., MD, Kastelein, John J.P., MD, PhD

“…Objectives The aim of this study was to evaluate the efficacy and safety of mipomersen in hypercholesterolemic subjects taking stable statin therapy…”
Get full text

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B by KASTELEIN, John J. P, WEDEL, Mark K, BAKER, Brenda F, SU, John, BRADLEY, Joann D, YU, Rosie Z, CHUANG, Emil, GRAHAM, Mark J, CROOKE, Rosanne M

“…Apolipoprotein B (apoB) is an important structural component of low-density lipoprotein cholesterol (LDL-C) and plays a key role in LDL-C transport and…”
Get full text

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data by Viney, Nicholas J., Guo, Shuling, Tai, Li‐Jung, Baker, Brenda F., Aghajan, Mariam, Jung, Shiangtung W., Yu, Rosie Z., Booten, Sheri, Murray, Heather, Machemer, Todd, Burel, Sebastien, Murray, Sue, Buchele, Gustavo, Tsimikas, Sotirios, Schneider, Eugene, Geary, Richard S., Benson, Merrill D., Monia, Brett P.

“…Aims Amyloidogenic transthyretin (ATTR) amyloidosis is a fatal disease characterized by progressive cardiomyopathy and/or polyneuropathy. AKCEA‐TTR‐LRx…”
Get full text

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia by Akdim, Fatima, MD, Visser, Maartje E., MD, Tribble, Diane L., PhD, Baker, Brenda F., PhD, Stroes, Erik S.G., MD, PhD, Yu, Rosie, PhD, Flaim, Joann D., PhD, Su, John, PhD, Stein, Evan A., MD, PhD, Kastelein, John J.P., MD, PhD

“…A randomized, double-blind, placebo-controlled, dose-escalation study was conducted to examine the efficacy and safety of mipomersen (ISIS 301012), an…”
Get full text

Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis by Dyck, P. James B., Coelho, Teresa, Waddington Cruz, Marcia, Brannagan, Thomas H., Khella, Sami, Karam, Chafic, Berk, John L., Polydefkis, Michael J., Kincaid, John C., Wiesman, Janice F., Litchy, William J., Mauermann, Michelle L., Ackermann, Elizabeth J., Baker, Brenda F., Jung, Shiangtung W., Guthrie, Spencer, Pollock, Michael, Dyck, Peter J.

“…Introduction Hereditary transthyretin‐mediated amyloidosis (hATTR) manifests as multisystem dysfunction, including progressive polyneuropathy. Inotersen, an…”
Get full text

Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events by Partridge, Wesley, Burel, Sebastien A., Ferng, Annie, Xia, Shuting, Kwoh, T. Jesse, Henry, Scott P., Baker, Brenda F.

“…This analysis sought to assess the clinical predictivity of an in vitro assay which utilized the human B‐lymphoma BJAB cell line, for identification of…”
Get full text

Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity by Kraynack, Bryan A, Baker, Brenda F

“…RNA interference (RNAi) is a process by which short interfering RNAs (siRNAs) direct the degradation of complementary single-strand RNAs. In this study, we…”
Get full text

Antisense technology: an overview and prospectus by Crooke, Stanley T., Baker, Brenda F., Crooke, Rosanne M., Liang, Xue-hai

“…Antisense technology is now beginning to deliver on its promise to treat diseases by targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs…”
Get full text

Positional Effect of Chemical Modifications on Short Interference RNA Activity in Mammalian Cells by Prakash, Thazha P, Allerson, Charles R, Dande, Prasad, Vickers, Timothy A, Sioufi, Namir, Jarres, Russell, Baker, Brenda F, Swayze, Eric E, Griffey, Richard H, Bhat, Balkrishen

“…A systematic study on the effect of 2‘-sugar modifications (2‘-F (2‘-F-2‘-deoxy-nucleoside residues), 2‘-O-Me (2‘-O-methyl-nucleoside residues), and 2‘-O-MOE…”
Get full text

Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics by Lee, Richard G., Crosby, Jeff, Baker, Brenda F., Graham, Mark J., Crooke, Rosanne M.

“…Antisense oligonucleotides and small interfering RNAs, which suppress the translation of specific mRNA target proteins, are emerging as important therapeutic…”
Get full text

Antisense technology: A review by Crooke, Stanley T., Liang, Xue-Hai, Baker, Brenda F., Crooke, Rosanne M.

“…Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA-targeted drugs including eight single-strand antisense drugs…”
Get full text